Company Filing History:
Years Active: 2003-2005
Title: Peter Habenberger: Innovator in Cellular Kinases and HBV Vectors
Introduction
Peter Habenberger is a notable inventor based in Munich, Germany. He has made significant contributions to the field of biotechnology, particularly in the areas of cellular kinases and hepatitis B virus (HBV) vectors. With a total of 2 patents, his work has implications for therapeutic advancements in viral infections.
Latest Patents
Habenberger's latest patents include "Cellular kinases involved in Cytomegalovirus infection and their inhibition" and "HBV vectors and cells for producing the same." The first patent discloses the role of certain cellular kinases that are active during Human Cytomegalovirus (HCMV) infection. These kinases are useful for detecting HCMV infection and screening for cellular kinase inhibitors. The inhibitors that effectively downregulate these key cellular components serve as promising therapeutics against HCMV infection. The second patent relates to an HBV vector in which functional genes of HBV are at least partially deleted. This invention also concerns a process for producing such an HBV vector, along with the cells that can be used for this purpose.
Career Highlights
Throughout his career, Peter Habenberger has worked with several prominent companies, including Axxima Pharmaceuticals AG and Mondogen GmbH. His experience in these organizations has allowed him to develop innovative solutions in the biotechnology sector.
Collaborations
Habenberger has collaborated with notable colleagues such as Daniel Schubart and Matthias Stein-Gerlach. These partnerships have contributed to the advancement of his research and inventions.
Conclusion
Peter Habenberger is a distinguished inventor whose work in cellular kinases and HBV vectors has the potential to impact therapeutic strategies for viral infections. His contributions to biotechnology continue to pave the way for future innovations.